https://www.selleckchem.com/pr....oducts/AZD2281(Olapa
y improved OS (adjusted hazard ratios [aHRs], 0.86; 95% CI, 0.66-1.12; P = .26; and aHR, 0.57; 95% CI, 0.38-0.85; P = . 005, respectively) and PFS (aHR, 0.68; 95% CI, 0.55-0.85; P = .001; and aHR, 0.39; 95% CI, 0.28-0.55; P .001, respectively) vs patients with no irAEs, in multivariable models adjusting for ICI duration. In this multicenter cohort study, development of multisystem irAEs was associated with improved survival in patients with advanced NSCLC treated with ICIs. In this multicenter cohort study, development of
Beğen
Yorum Yap
Paylaş
